Concepedia
Statistics
Publications
14
Citations
821
H-Index
13
Active since
2013
Affiliations
Weizmann Institute of Science(Current)
Institut de Recherche en Cancérologie de Montpellier
Inserm
Universidade do Porto
German Cancer Research Center
Maicol Mancini is an author at Weizmann Institute of Science specializing in molecular oncology, oncology, and medicine.
Publications per year
2013–2021
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Georg Mahlknecht, Ruth Maron, Maicol Mancini et al. · Proceedings of the National Academy of Sciences · 2013 · 161 citations · Full text
Medicine, Molecular Biology, Oncology +15
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Donatella Romaniello, Luigi Mazzeo, Maicol Mancini et al. · Clinical Cancer Research · 2018 · 85 citations · Full text
Medicine, Oncology, Pharmacology +17
EGF induces microRNAs that target suppressors of cell migration: miR-15b targets <i>MTSS1</i> in breast cancer
Merav Kedmi, Nir Ben‐Chetrit, Cindy Körner et al. · Science Signaling · 2015 · 81 citations · Full text
Medicine, Cancer Biology, Oncology +17
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
Nir Ben‐Chetrit, David Chetrit, Roslin Russell et al. · Science Signaling · 2015 · 78 citations · Full text
Medicine, Molecular Biology, Oncology +17
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron, Bilha Schechter, Maicol Mancini et al. · Proceedings of the National Academy of Sciences · 2013 · 57 citations · Full text
Medicine, Oncology, Pharmacology +15
1–5 of 14